3,030,845 Shares in MAIA Biotechnology, Inc. $MAIA Acquired by Solas Capital Management LLC

Solas Capital Management LLC acquired a new stake in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 3,030,845 shares of the company’s stock, valued at approximately $4,364,000. MAIA Biotechnology accounts for about 2.3% of Solas Capital Management LLC’s portfolio, making the stock its 16th biggest holding.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MAIA. Marshall Wace LLP acquired a new stake in MAIA Biotechnology during the 2nd quarter worth $29,000. PVG Asset Management Corp acquired a new stake in shares of MAIA Biotechnology in the first quarter valued at about $46,000. Jane Street Group LLC acquired a new stake in shares of MAIA Biotechnology in the second quarter valued at about $52,000. Corsair Capital Management L.P. acquired a new stake in shares of MAIA Biotechnology in the first quarter valued at about $140,000. Finally, Geode Capital Management LLC lifted its stake in shares of MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after buying an additional 7,746 shares in the last quarter. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Trading Down 2.9%

MAIA opened at $1.35 on Tuesday. The firm has a market capitalization of $82.12 million, a PE ratio of -2.18 and a beta of 0.24. MAIA Biotechnology, Inc. has a twelve month low of $0.87 and a twelve month high of $3.19. The firm’s 50-day moving average price is $1.37 and its 200 day moving average price is $1.46.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, analysts predict that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Stan Smith purchased 75,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was purchased at an average price of $1.34 per share, with a total value of $100,500.00. Following the completion of the acquisition, the director owned 1,519,178 shares in the company, valued at $2,035,698.52. This trade represents a 5.19% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Vlad Vitoc purchased 72,700 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was bought at an average cost of $1.39 per share, with a total value of $101,053.00. Following the acquisition, the chief executive officer owned 976,121 shares of the company’s stock, valued at approximately $1,356,808.19. The trade was a 8.05% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 161,599 shares of company stock worth $220,535 over the last three months. Corporate insiders own 19.81% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.